Want to see VERU full AI Analyst Report?
VERU Stock Chart & Stats
$2.25
$0.07(3.11%)
At close: 4:00 PM EDT
$2.25
$0.07(3.11%)
Day’s Range― - ―
52-Week Range$2.05 - $7.33
Previous CloseN/A
Volume259.51K
Average Volume (3M)322.51K
Market Cap
$45.01M
Enterprise Value$49.04
Total Cash (Recent Filing)$23.88M
Total Debt (Recent Filing)$2.68M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Nov 26, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding17,050,320
10 Day Avg. Volume249,288
30 Day Avg. Volume322,506
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-1.85
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Study SuccessThe Ph. IIb QUALITY study has achieved full enrollment of over 150 patients, with top-line data expected to provide insights into enobosarm's effectiveness.
Potential PartnershipsPositive results from the QUALITY trial could help the company secure a partnership before advancing enobosarm into a pivotal program for the treatment of obesity.
Strategic Business MovesVERU has strategically monetized its FC2 female condom business for $18M to focus solely on enobosarm's development.
Bears Say
Market CompetitionThe ease of administration for enobosarm (an oral drug) compares favorably to other competing treatment options that require intravenous administration.
Stock VolatilityA significant intra-day stock sell-off was attributed to the lack of meaningful weight loss benefits observed during the initial period of the study.
Study ChallengesThe ongoing Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for the treatment of sarcopenic obesity is on track to report topline data in January 2025.
Veru News
VERU FAQ
What was Veru’s price range in the past 12 months?
Veru lowest stock price was $2.05 and its highest was $7.33 in the past 12 months.
What is Veru’s market cap?
Veru’s market cap is $45.01M.
When is Veru’s upcoming earnings report date?
Veru’s upcoming earnings report date is Nov 26, 2026 which is in 93 days.
How were Veru’s earnings last quarter?
Veru released its earnings results on Aug 10, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.32 by $0.02.
Is Veru overvalued?
According to Wall Street analysts Veru’s price is currently Overvalued.
Does Veru pay dividends?
Veru pays a Quarterly dividend of $0.07 which represents an annual dividend yield of N/A. See more information on Veru dividends here
What is Veru’s EPS estimate?
Veru’s EPS estimate is -0.33.
How many shares outstanding does Veru have?
Veru has 17,050,320 shares outstanding.
What happened to Veru’s price movement after its last earnings report?
Veru reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.32. Following the earnings report the stock price went up 18.884%.
Which hedge fund is a major shareholder of Veru?
Currently, no hedge funds are holding shares in VERU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veru Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 653.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-62.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.48%
Trailing 12-Months
Company Description
Veru
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
VERU Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple meaningful positive developments: full enrollment of the Phase IIb PLATEAU study with an upcoming interim analysis, demonstration of muscle-preserving benefits in the prior QUALITY study, a strategic Novo Nordisk supply agreement, a notice of allowance for a key U.S. method-of-use patent (extending protection into the 2040s), improved cash and working capital driven by a financing and realizations, and year-to-date reductions in net loss and operating cash burn. Offsetting these positives are continued net losses, ongoing negative operating cash flow, a near-term increase in R&D spend tied to PLATEAU, strong competitive pressures from established GLP-1 players, and some commercial constraint from Novo's right of first negotiation. On balance, the company showed clear progress on clinical, IP and financing fronts sufficient to fund near-term milestones, but it continues to face execution, clinical and competitive risks.View all VERU earnings summariesTechnical Analysis
Karyopharm Therapeutics
―
Cue Biopharma
―
Inmune Bio
―
Celularity
―
Jupiter Neurosciences, Inc.
―